Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation

Diabetes

Volumn 65, Issue 11, 2016, Pages 3473-3481

  Færch, Kristine ^a   Vistisen, Dorte ^a   Pacini, Giovanni ^b   Torekov, Signe S ^c,d   Johansen, Nanna B ^a,e   Witte, Daniel R ^e,f   Jonsson, Anna ^c   Pedersen, Oluf ^c   Hansen, Torben ^c   Lauritzen, Torsten ^f   Jørgensen, Marit E ^a   Ahrén, Bo ^g   Holst, Jens Juul ^c,d  

^a STENO DIABETES CENTER   (Denmark)

^b CNR   (Italy)

^c Capital Region   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e DANISH DIABETES ACADEMY   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; BLOOD; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 84994259654     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0240     Document Type: Article

References (35)

1. Ahrén B. Glucagon-early breakthroughs and recent discoveries. Peptides 2015;67:74-81
2. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723
3. Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970;49: 837-848
4. Reaven GM, Chen Y-Di, Golay A, Swislocki ALM, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64:106-110
5. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007;50:797-805
6. Færch K, Vaag A, Holst JJ, Glümer C, Pedersen O, Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008;51:853-861
7. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-29
8. Borghi VC, Wajchenberg BL, Cesar FP. Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism 1984;33:1068-1074
9. Ahrén B. Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia 2006;49:117-122
10. Larsson H, Ahrén B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 2000;23:650-657
11. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007;56:1951-1959
12. Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 2007;50:806-813
13. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116
14. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304
15. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009;58:1342-1349
16. Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004;150:97-104
17. Johansen NB, Hansen AL, Jensen TM, et al. Protocol for ADDiTION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health 2012;12: 1078
18. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G; Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care. The ADDiTION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24(Suppl. 3):S6-S11
19. Færch K, Torekov SS, Vistisen D, et al. Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screen-detected type 2 diabetes and obesity, and influenced by sex: the ADDiTION-PRO Study. Diabetes 2015;64:2513-2525
20. Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 2014;57:1919-1926
21. Lund A, Bagger JI, Wewer Albrechtsen NJ, et al. Evidence of extrapancreatic glucagon secretion in man. Diabetes 2016;65:585-597
22. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 1983;24:359-365
23. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-539
24. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011;96:2519-2524
25. Møller CL, Vistisen D, Færch K, et al. Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDiTION-PRO Study. J Clin Endocrinol Metab 2016;101:485-493
26. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 2000;47:177-184
27. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835, ix
28. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672
29. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the Gut in Glucose Homeostasis. Diabetes Care 2016;39:884-892
30. Færch K, Pacini G, Nolan JJ, Hansen T, Tura A, Vistisen D. Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs. Diabetes Care 2013;36:3691-3697
31. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 2013;36:1396-1405
32. Ferrannini E, Muscelli E, Natali A, et al.; Relationship between Insulin Sensitivity and Cardiovascular Disease Risk (RISC) Project Investigators. Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia 2007;50:2342-2347
33. Østoft SH, Bagger JI, Hansen T, et al. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young-type 2 and type 3. Diabetes 2014;63:2838-2844
34. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008;51:2263-2270
35. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-388